General introduction 29 1 37. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine 2021; 9(12): 1407-18. 38. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine 2020; 383(19): 1813-26. 39. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020; 383(27): 2603-15. 40. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet 2021; 397(10277): 881-91. 41. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine 2020; 384(5): 403-16. 42. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. The Lancet Infectious Diseases 2022; 22(9): 1293-302. 43. Lazarus JV, Karim SSA, Batista C, Rabin K, El-Mohandes A. Vaccine inequity and hesitancy persist—we must tackle both. BMJ 2023; 380: p8. 44. Bijkerk PH, G.B.; van der Plas, S.M.; Siebbeles, M.F.; Timen, A.; van ‘t Veen, A.; van Vliet, J.A.; Westerhof, G.R. Melden van infectieziekten conform de Wet publieke gezondheid (2008). Amesfoort: RIVM, 2008. Report No.: 978 90 6960 206 6. 45. Rosenbaum L. Facing Covid-19 in Italy — Ethics, Logistics, and Therapeutics on the Epidemic’s Front Line. New England Journal of Medicine 2020; 382(20): 1873-5. 46. Desson Z, Lambertz L, Peters JW, Falkenbach M, Kauer L. Europe’s Covid-19 outliers: German, Austrian and Swiss policy responses during the early stages of the 2020 pandemic. Health Policy and Technology 2020; 9(4): 405-18. 47. Man diagnosed with coronavirus (COVID-19) in the Netherlands. Ministry of Health, Welfare and Sport: Government of the Netherlands, 2020. 48. New measures to stop spread of coronavirus in the Netherlands. Ministry of Health, Welfare and Sport: Government of the Netherlands, 2020. 49. Epidemiologische situatie COVID-19 in Nederland 1 juni 2020. Ministry of Health, Welfare and Sport: Government of the Netherlands, 2020. 50. Rijksoverheid. Nieuwe maatregelen tegen verspreiding coronavirus in Nederland. 2020. 51. Santomauro DF, Mantilla Herrera AM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet 2021; 398(10312): 1700-12. 52. Garcia EW, Elaine. COVID-19 and student performance, equity, and U.S. education policy. Economic Policy Institute 2020. 53. Brodeur A, Gray D, Islam A, Bhuiyan S. A literature review of the economics of COVID-19. J Econ Surv 2021: 10.1111/joes.12423. 54. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious Diseases 2022; 22(1): 35-42.
RkJQdWJsaXNoZXIy MTk4NDMw